← Back to Home

New Catheter-Based Repair Option for Tricuspid Regurgitation: Edwards’ PASCAL Precision Receives FDA Approval

For patients who remain severely symptomatic after drug therapy and face higher surgical risk, this approval adds a valve repair option; one-year results from the pivotal trial are scheduled for presentation at the TCT conference beginning later this month.

By SURL BioNews

When a heart valve does not close properly, patients who remain symptomatic after drug therapy often also face the question of whether they can tolerate surgery. Edwards Lifesciences announced on October 21 that the U.S. Food and Drug Administration (FDA) had approved the PASCAL Precision system for tricuspid valve repair, adding a catheter-based treatment option for eligible patients with severe tricuspid regurgitation.

According to the indication announced by the company, patients must have symptomatic severe tricuspid regurgitation despite optimal medical therapy and be at moderate or greater surgical risk. Suitability for transcatheter tricuspid edge-to-edge repair (T-TEER) must also be assessed by a multidisciplinary heart team, including whether the valve anatomy is suitable for treatment. The approved use focuses on improving quality of life and functional status.

The tricuspid valve lies between the right atrium and right ventricle; when it does not close completely, blood flows backward. PASCAL repairs the valve by using an implanted device to grasp and bring the valve leaflets together, helping the valve close and reducing regurgitation. This approach preserves the native valve and differs from replacement treatment, which directly implants a prosthetic valve.

According to medical device news outlet MassDevice, PASCAL Precision received FDA approval for mitral regurgitation as early as 2022. Its expansion to the tricuspid valve places it alongside Edwards’ existing Evoque tricuspid valve replacement system, providing two treatment pathways: repair and replacement. However, more options do not mean the two are interchangeable, and patients still require individual assessment.

The pivotal clinical evidence supporting this treatment will soon undergo more comprehensive public scrutiny. Edwards said one-year follow-up data from the CLASP IITR pivotal trial are scheduled for presentation in a late-breaking research session at the Transcatheter Cardiovascular Therapeutics (TCT) conference; MassDevice noted that the meeting will take place from October 31 to November 3 in San Diego, United States.

The company’s announcement currently provides no specific efficacy or adverse event figures from these one-year data, so the extent of improvement patients may experience cannot yet be quantified on that basis, nor can this approval be interpreted as proof of prolonged survival. For patients and medical teams, the significance of the new option is an additional treatment pathway to assess; the magnitude of its benefits, its risks, and its durability remain to be clarified by the full trial results.

References

  1. Edwards Lifesciences
  2. MassDevice